Showing results (51-60 of 97) with videos related to
Sort By:
Pageof 10
Drugs|July 20, 2021
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis SuppurativaPim Aarts, Koen Dudink, Allard R J V Vossen, et al.Experimental Dermatology|June 4, 2021
Anti-COVID-19 measurements for hidradenitis suppurativa patientsEvangelos J Giamarellos-Bourboulis, Vincenzo Bettoli, Gregor B E Jemec, et al.Dermatology and Therapy|March 9, 2023
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled TrialAlexa B Kimball, Errol P Prens, Thierry Passeron, et al.Therapeutic Drug Monitoring|June 2, 2017
Prolongation of Biologic Dosing Intervals in Patients With Stable Psoriasis: A Feasibility StudyJi S van Bezooijen, Martijn B A van Doorn, Marco W J Schreurs, et al.Plos One|May 26, 2011
GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4Emoke Rácz, Dorota Kurek, Marius Kant, et al.Therapeutic Drug Monitoring|July 11, 2017
Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance TreatmentJi S van Bezooijen, Marco W J Schreurs, Birgit C P Koch, et al.Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.Arthritis & Rheumatology (Hoboken, N.J.)|April 4, 2020
Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis SynovitisXiaofei Xu, Nadine Davelaar, Anne-Marie Mus, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2009
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axisLeslie van der Fits, Sabine Mourits, Jane S A Voerman, et al.Experimental Dermatology|May 31, 2022
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept studyAlexa B Kimball, Christian Loesche, Errol P Prens, et al.Pageof 10